CD19 and skin neoplasm: The drastic reduction of B cells (CD19+), from 48.44% at the start of treatment to 1.71% at the time of skin tumor diagnosis, demonstrated the potent targeting of Orelabrutinib in controlling MCL, while a significant increase in total T cell (CD3+) and helper T cell (CD4+) numbers was observed (Table 1).